In order to determine whether differences in body fat distribution result in specific abnormalities of free fatty acid (FFA) metabolism, palmitate turnover, a measure of systemic adipose tissue lipolysis, was measured in 10 women with upper body obesity, 9 women with lower body obesity, and 8 nonobese women under overnight postabsorptive (basal), epinephrine stimulated and insulin suppressed conditions. Results: Upper body obese women had greater (P < 0.005) basal palmitate turnover than lower body obese or nonobese women (2.8±0.2 vs. 2.1±0.2 vs. 1.8±0.2 Mmolt kg lean body mass (LBM)-1 * min-, respectively), but a reduced (P < 0.05) net lipolytic response to epinephrine (59±7 vs. 79±5 vs. 81±7 Mmol palmitate/kg LBM, respectively). Both types of obesity were associated with impaired suppression of FFA turnover in response to euglycemic hyperinsulinemia compared to nonobese women (P < 0.005). These specific differences in FFA metabolism may reflect adipocyte heterogeneity, which may in turn affect the metabolic abberations associated with different types of obesity. These findings emphasize the need to characterize obese subjects before studies.
Introduction
Plasma free fatty acids (FFA) , originating from the release of adipose tissue triglyceride fatty acid, represent virtually the only route by which these fat stores can be transferred to nonfat tissue for net loss via oxidation. Free fatty acid metabolism in obesity has, therefore, been the subject of many studies over the last thirty years. Unfortunately, conflicting conclusions regarding several aspects of FFA metabolism have appeared, including the antilipolytic effectiveness ofinsulin in obesity (1, 2) , the relationship of FFA release to the amount of body fat (3) (4) (5) , and the lipolytic responsiveness of obese individuals to catecholamines (6) (7) (8) . These potential differences in FFA metabolism between lean and obese humans may be of considerable importance in that they reflect either abnormalities of adipose tissue or of the body's ability to hormonally regulate adipose tissue lipolysis. Plasma FFA concentrations may not accurately reflect FFA flux (i.e., effective adipose tissue lipolysis) in obesity (9) ; isotope dilution studies are, therefore, necessary in order to measure lipolysis in vivo (9) .
It is now clear that obesity is a heterogeneous disorder. Moderately obese women with waist to hip circumference ratios (WHR)' of greater than 0.85 (upper body obesity) have an increased risk of hypertriglyceridemia, glucose intolerance, hypertension (10) , and insulin resistance with regards to glucose metabolism (1 1), whereas women with lower body obesity (WHR less than 0.76) (10, 11) do not. Thus, characterization of body fat distribution is important in planning metabolic studies of obesity.
Although the relationship between adipocyte heterogeneity and metabolic complications of obesity is not clear, it is interesting to note that adipocytes from various body regions differ from one another in many respects. Fat cell size and basal lipolysis vary in adipocytes from omental, abdominal subcutaneous, and gluteal-thigh adipose tissue depots (12-14). In addition, differences in the ability of insulin to suppress lipolysis (14) and of catecholamines to stimulate lipolysis ( 13) are present. Ifthese in vitro differences are reflected in vivo, abnormalities might develop which could influence the metabolic manifestations of obesity. Increased FFA flux is associated with hypertriglyceridemia (15) and failure to suppress lipolysis could result in glucose intolerance via the glucose-fatty acid cycle (16, 17) . Thus, differences in body fat distribution, by altering the proportions of lipolytically dissimilar adipocytes, could play a role in the obesity phenotypes. The present study was undertaken to determine whether differences in body fat topography in healthy, obese women are associated with specific abnormalities of FFA metabolism.
Methods
Subjects. Informed (26) concentrations were measured by radioimmunoassay, and plasma epinephrine and norepinephrine were measured by radioenzymatic assay (27) . Plasma glucose concentrations were determined by glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH) and glucose specific activity was determined as previously described (28) . Protocol. Each subject underwent lean body mass (LBM) determination by tritiated water space and/or body potassium counting (29) before the studies, which were performed in the follicular phase ofeach woman's menstrual cycle in order to eliminate the confounding variable ofchanging serum estrogen concentrations (30) . The glucose were begun and continued through +60 min. From time 0 to 60 min, subjects received an intravenous infusion of epinephrine, diluted in 0.9% saline containing 1 mg/ml ascorbic acid (to prevent epinephrine degradation), at a rate of 17 ng * kg LBM-' min-'. Pulse and blood pressure were monitored on two occasions from -30 to 0 min and at 10-min intervals from 0 to 60 min. The subjects returned 3 d later and were studied in an identical fashion, except that they received intravenous insulin (0.14 mU/kg LBM bolus and 0.20 mU * kg LBM-' -min-' constant infusion) throughout the entire study, including the epinephrine infusion. A variable rate intravenous infusion of 50% dextrose was administered during the second study in order to maintain each subject's plasma glucose concentration at the values observed on the first study day.
Blood was sampled before starting the isotope infusions on each study day and assayed for palmitate and glucose SA to serve as background for that day. Blood samples were obtained at -150 min and at 10-min intervals from -30 to +60 min on each study day and analyzed for plasma concentrations of FFA, glucose, insulin, C-peptide, glucagon, growth hormone, epinephrine, norepinephrine, palmitate, and palmitate and glucose SA. In addition, plasma glucose concentrations were measured at 10-min intervals throughout the second study to assist in determining the amount of dextrose to be infused in order to maintain euglycemia.
Calculations. Plasma palmitate and glucose concentrations and specific activity were constant from -30 to 0 min during both the baseline and the insulin clamp study days; therefore, steady state conditions were assumed for these study intervals. Palmitate rate of appearance (Ra) into the systemic circulation was calculated using steady state equations as previously described (21); these equations accurately estimate FFA Ra under conditions of changing plasma FFA concentrations (21) .
During the epinephrine infusion, palmitate and glucose specific activity and concentrations were not constant. The lipolytic response to epinephrine was calculated by determining both the area under the curve above baseline palmitate Ra and the peak increment in palmitate Ra (19, 21) . During the epinephrine infusion, glucose Ra and disappearance (Rd) were calculated using nonsteady-state equations (32) . These equations have been tested and found to perform reasonably well (33), even under conditions of much more abrupt perturbations in glucose Ra than those observed in the present study. The known exogenous glucose infusion rate during the insulin clamp was subtracted from the total glucose Ra over each ten minute time interval and used to calculate the endogenous glucose Ra. Net additional endogenous glucose release in response to epinephrine was calculated as the area under the curve above baseline. Plasma hormone concentrations were constant during the -30-0-min study interval on both study days; therefore, mean values for each subject were determined and used to calculate group means.
All results were expressed as mean±SEM. Statistical comparisons between the same study periods among groups were performed using analysis of variance and subsequent Duncan's test. Comparisons between the same study periods on the saline control vs. the insulin clamp studies in the same group were made using a two-tailed paired Student's t test, as were comparisons between one time interval and another on the same study day.
Results
Subject characteristics (Tables I and II) Women with upper body and lower body obesity did not differ with respect to their degree of overweight, percent body fat, or total lean body mass. The mean ages of the women in the different groups was not different and their serum cholesterol concentrations were similar.
The serum triglyceride concentrations were greater in upper body obese women (P < 0.001) than lower body obese or nonobese women, whose concentrations were not different from each other. As anticipated, the nonobese women had less body fat (P < 0.001) than either group of obese women. The baseline plasma insulin and C-peptide concentrations were significantly different (P < 0.001) among all three groups, with upper body obese women having the highest values for both, nonobese women having the lowest, and lower body obese women having intermediate concentrations. Plasma growth hormone concentrations were less in the upper body obese women than the nonobese women (P < 0.05); however, concentrations in the lower body obese women were not different than in the other groups. Plasma glucagon, epinephrine, and norepinephrine concentrations were similar among the three groups. (Tables II to III) . When plasma insulin concentrations were increased by 4-7 uU/ml (Table II) during the insulin clamp, a significant (P < 0.01) reduction in plasma palmitate concentrations and flux occurred in all groups when compared to the baseline study. Plasma palmitate and FFA concentrations and flux during the insulin clamp were less (P < 0.005) in the nonobese women than either group of obese women.
Response to epinephrine (Table III , Fig. 1-3 ). During the epinephrine infusion on the first study day, the mean plasma insulin ( Fig. 1) and C-peptide concentrations increased slightly (4.5 to 5.8 ,U/ml, and 0.81 to 0.97 ng/ml, respectively, both P < 0.001) in the nonobese women, but were unchanged in either group of obese women. The mean plasma epinephrine and norepinephrine concentrations during the baseline study epinephrine infusion were 208±24, 196±14, and 190±14 pg/ml (P = NS) and 182±17, 180±18, and 166±13 pg/ml (P =-NS) in upper body obese, lower body obese, and nonobese women, respectively. The intravenous epinephrine infusion during the insulin clamp study resulted in plasma epinephrine and norepinephrine concentrations of 205±27, 186±11, and 185±14 pg/ml (P = NS) and 184+14, 182±16, and 177±14 pg/ml (P = NS), in upper body obese, lower body obese, and nonobese women, respectively. Plasma glucagon and growth hormone concentrations did not change in response to epinephrine. Upper body obese, lower body obese, and nonobese women did not differ with regards to the peak increment responses of pulse (+ 13±1 vs. +9±1 vs. + 12±2 bpm, respectively), systolic (+ 11±2 vs. +5±4 vs. +5±2 mmHg, respec- (Fig. 2) . Upper body obese women had a reduced (P < 0.05) lipolytic response (area under the curve above baseline palmitate rate of appearance) to epinephrine when compared with those of the lower body obese or nonobese women, whose responses did not differ. The peak increment in palmitate Ra in response to epinephrine was less (P < 0.05) in upper body obese women than nonobese women, while the response in lower body obese women was not significantly different from either of the other groups. The lipolytic responses to epinephrine infusion during the insulin clamp study (Fig. 3) were slightly, but not significantly less in each group of women than during the baseline epinephrine infusion (Fig. 2) .
Glucose kinetics (Table IV, Figs. 4 and 5). Baseline plasma glucose concentrations and flux were not different among the three groups of women. During the insulin clamp study, despite significantly lower plasma insulin concentrations, the nonobese women were found to have greater glucose utilization and less endogenous glucose production than either group of obese women (both P < 0.05).
Intravenous epinephrine resulted in an increase in plasma glucose concentrations on the first study day, which were matched during the epinephrine infusion on the insulin clamp study day (Fig. 4) response to epinephrine (Fig. 5 ) was highly variable and not significantly different (P = 0.1 1) between the three groups of women. Euglycemic hyperinsulinemia did not affect the net additional endogenous glucose response to epinephrine (Fig. 5 , Table IV) .
Discussion
These studies demonstrate, for the first time, that in healthy, age-matched, moderately obese women, body fat topography is predictive of specific abnormalities in FFA metabolism. Despite the absence ofdifferences in postabsorptive glucose transport, upper body obese women, but not lower body obese women had increased adipose tissue FFA release relative to lean body mass. Mild hyperinsulinemia resulted in less complete suppression of lipolysis in both types of obese women, and intravenous epinephrine resulted in a reduced net lipolytic response only in upper body obese women. Plasma palmitate and FFA concentrations alone did not distinguish the extent of the differences between these two groups of women; only by measuring FFA turnover could these abnormalities be detected.
The magnitude of the differences in FFA flux between these three groups of women is considerable. Increased FFA availability is necessary for optimal metabolic function in situations such as fasting (39) and exercise (40) . Intravenous epinephrine infusions have been used to test for defects in the ability of obese persons to enhance lipolysis (6) (7) (8) , however, conflicting findings have been reported (6) (7) (8) . In this study, the lipolytic response to epinephrine was reduced in upper body obese women compared with lower body obese and nonobese women. This difference could explain the discrepancies between the previous reports. The reduced lipolytic effect of epinephrine in upper body obese women is not due to generalized hyporesponsiveness to catecholamines, because increases in blood pressure, pulse, and hepatic glucose release in this group were not different than those observed in the other two groups. This abnormality in upper body obese women is consistent with in vitro studies using subcutaneous abdominal adipose tissue; adipocytes from upper body obese women increased lipolysis only 34% in response to epinephrine compared with a 139% increase in fat cells from lower body obese women (18) . If this reduced ability to enhance lipolysis extends to circumstances such as caloric restriction (38) or exercise (3) , this abnormality could affect treatment approaches for upper body obese individuals. Further studies are needed to answer these questions.
Although most investigators normalize FFA flux values to lean body mass (3) (4) (5) 38) , the tissues most likely to be consuming FFA as a metabolic fuel, it should be acknowledged that alternative modes of data presentation have been chosen (38) . In the present study, upper body obese women had greater basal FFA flux than lower body obese women (data not shown), whether expressed in terms of total body weight (1.5±0.1 vs. 1.1±0.1 smol palmitate kg-' *min', respectively, P < 0.05) or fat mass (3.0±0.2 vs. 2.3±0.2 Mmol palmitate* kg fat mass-' * min-', respectively, P < 0.05). Thus, differences in regulation of adipose tissue lipolysis between these two types of human obesity are evident independent of the method of data analysis.
In summary, the basal release of FFA from adipose tissue to meet lean body mass energy needs is greater in upper body obese women than lower body obese or nonobese women. In addition, small increments in plasma insulin concentration obtained using the euglycemic clamp technique resulted in significantly lower FFA flux in nonobese women compared with obese women, and this was associated with greater glucose disposal and lower endogenous glucose production in the nonobese women. The net lipolytic response to epinephrine is reduced in upper body obese women compared with lower body obese and nonobese women. Some of these observed differences are consistent with in vitro data regarding the regional differences in adipocyte kinetics. Our results may explain many ofthe conflicting reports in the literature regarding FFA metabolism in human obesity and emphasize the need to characterize the type of obesity being studied before investigations of FFA metabolism in humans.
